Key result
COVID-19 exacerbates underlying cardiovascular conditions and may cause direct myocardial injury, highlighting the need for rigorous clinical trials to evaluate the cardiac safety and efficacy of emerging treatments like cell therapy.
Why the study?
Understanding how COVID-19 affects patients with underlying cardiovascular disease is essential to manage and improve clinical strategies in this population.
This review highlights the significant cardiovascular implications of COVID-19 infection and its potential therapies, emphasizing the need for careful monitoring of cardiac toxicity and the continuation of RAAS inhibitors in patients with pre-existing cardiovascular conditions.
Supports cardiac monitoring in COVID-19; leaves open cell therapy safety and efficacy for dedicated trials.
While the COVID-19 pandemic continues to spread rapidly, resulting in considerable morbidity and mortality worldwide, multiple efforts are being made by the international scientific community to understand the pathogenesis of the viral infection and its clinical outcome. Older age and comorbidities have consistently been reported as risk factors for unfavorable prognosis, with cardiovascular disease accounting for up to 10 % of comorbid conditions among the infected patients. An understanding of the mechanism underlying the effect of this infection on patients with cardiovascular disease is essential to manage and improve clinical strategies against the disease in that population. In this review, we summarize the impact of COVID-19 on patients with underlying cardiovascular conditions and the cardiac implications of known and emerging therapeutic strategies. Our future effort will aim to further elucidate how the type and severity of the cardiac disease, with particular regard to Congenital Heart Disease, influences the prognosis and the outcome of the viral infection.
No takes yet. Share an insight, caveat, or question.
Iacobazzi et al. (2020) conducted a review in COVID-19 and Cardiovascular Disease. COVID-19 therapeutics and cell therapy was evaluated. COVID-19 exacerbates underlying cardiovascular conditions and may cause direct myocardial injury, highlighting the need for rigorous clinical trials to evaluate the cardiac safety and efficacy of emerging treatments like cell therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: